1 INTRODUCTION Glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment elicits significant long-term protection against negative cardiovascular and renal outcomes in patients with type 2 diabetes (Marso Bain, et al., 2016; Marso, Daniels, et al., 2016; Perkovic et al., 2024).
Ali Asmar
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Ali
Contact Ali, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack